---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-014850"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:36:10.435291+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FDA lifts full clinical hold on Inhibikase's IkT-148009 for Parkinson's; Phase 2a trial restarting

## Summary
- FDA lifted full clinical hold on IkT-148009; Phase 2a 201 trial resumes at 50 and 100 mg doses.
- Company will measure safety and steady-state PK of 200 mg in 6 healthy subjects before PD patient dosing.
- Expanded ocular monitoring includes cornea/lens; no ocular pathology observed to date.
- Inhibikase intends to seek lift of clinical hold on its Multiple System Atrophy (MSA) program.
- Publication in Science Translational Medicine shows IkT-148009 halts neurodegeneration and reduces alpha-synuclein pathology in mouse models.

## SEC filing metadata
- accession: 0001193125-23-014850
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312523014850/0001193125-23-014850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312523014850/d439029d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-014850
- JSON: https://secwatch.observer/filing/0001193125-23-014850.json
- Plain text: https://secwatch.observer/filing/0001193125-23-014850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.